Stock Yards Bank & Trust Co. increased its holdings in Amgen, Inc. (NASDAQ:AMGN) by 0.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,424 shares of the medical research company’s stock after acquiring an additional 72 shares during the period. Stock Yards Bank & Trust Co.’s holdings in Amgen were worth $2,223,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of AMGN. Quadrant Capital Group LLC increased its stake in Amgen by 15.2% in the 4th quarter. Quadrant Capital Group LLC now owns 6,686 shares of the medical research company’s stock valued at $1,583,000 after buying an additional 883 shares during the last quarter. Strategy Asset Managers LLC purchased a new stake in Amgen in the 4th quarter valued at about $264,000. Banco Bilbao Vizcaya Argentaria S.A. purchased a new stake in Amgen in the 4th quarter valued at about $2,529,000. Vigilare Wealth Management purchased a new stake in Amgen in the 4th quarter valued at about $447,000. Finally, CSat Investment Advisory L.P. increased its stake in Amgen by 43.5% in the 4th quarter. CSat Investment Advisory L.P. now owns 1,576 shares of the medical research company’s stock valued at $380,000 after buying an additional 478 shares during the last quarter. Institutional investors own 75.73% of the company’s stock.

Several equities research analysts have commented on AMGN shares. Zacks Investment Research upgraded shares of Amgen from a “hold” rating to a “buy” rating and set a $240.00 price objective for the company in a research note on Wednesday, April 15th. Mizuho reissued a “hold” rating and set a $215.00 target price on shares of Amgen in a research report on Thursday, April 30th. Cfra increased their target price on shares of Amgen from $223.00 to $259.00 and gave the company a “buy” rating in a research report on Friday, May 1st. Wells Fargo & Co increased their target price on shares of Amgen from $220.00 to $237.00 and gave the company an “equal weight” rating in a research report on Friday, May 1st. Finally, Bank of America increased their target price on shares of Amgen from $250.00 to $265.00 and gave the company a “buy” rating in a research report on Friday, May 1st. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and eighteen have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $245.85.

Shares of Amgen stock traded up $3.05 on Tuesday, hitting $253.09. 2,343,790 shares of the company traded hands, compared to its average volume of 3,024,536. The company has a market cap of $146.50 billion, a P/E ratio of 19.53, a P/E/G ratio of 2.13 and a beta of 0.94. The firm’s 50-day simple moving average is $234.07 and its 200 day simple moving average is $226.11. Amgen, Inc. has a 12-month low of $173.12 and a 12-month high of $264.97. The company has a current ratio of 1.59, a quick ratio of 1.28 and a debt-to-equity ratio of 3.16.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $4.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.70 by $0.47. The business had revenue of $6.16 billion for the quarter, compared to analyst estimates of $6.01 billion. Amgen had a net margin of 32.03% and a return on equity of 90.75%. The company’s revenue was up 10.9% on a year-over-year basis. During the same quarter last year, the firm earned $3.56 EPS. Analysts predict that Amgen, Inc. will post 15.56 earnings per share for the current year.

In other Amgen news, Director R Sanders Williams sold 425 shares of the firm’s stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $237.31, for a total value of $100,856.75. Following the sale, the director now owns 5,834 shares of the company’s stock, valued at approximately $1,384,466.54. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Ronald D. Sugar sold 1,000 shares of Amgen stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $228.54, for a total transaction of $228,540.00. Following the sale, the director now directly owns 16,576 shares in the company, valued at approximately $3,788,279.04. The disclosure for this sale can be found here. In the last three months, insiders sold 3,425 shares of company stock worth $792,017. Insiders own 0.36% of the company’s stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Featured Story: What is a SEC Filing?

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.